Australia vs Korea: The number of people with susceptibility test result for rifampicin
Australia
83.5
in 2021
Korea
82.06
in 2021
Australia rank
90th
Korea rank
91st
The number of people with susceptibility test result for rifampicin over time
- Australia
- Korea
How they compare
Australia currently reports 83.5 against 82.06 in Korea, a difference of 1.44.
Across all 5 years both countries report, Australia has been ahead every year.
Australia ranks 90th and Korea ranks 91st of 146 countries.
Australia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Australia | Korea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 92.62 | 84.51 | 8.11 | Australia |
| 2020s | 88.8 | 85.46 | 3.34 | Australia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Australia or Korea?
- Australia, at 83.5 against 82.06 in Korea as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Australia and Korea?
- 1.44, with Australia ahead.
- How many years of comparable data are there for Australia and Korea?
- 5 years are reported by both, from 2017 to 2021.
- How do Australia and Korea rank globally for the number of people with susceptibility test result for rifampicin?
- Australia ranks 90th and Korea ranks 91st of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.